Federal and state policies regulating short‐term limited‐duration insurance plans and timely cancer treatment initiation
Cancer · 2026
DOI: 10.1002/cncr.70190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Jingxuan Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Surveillance, Prevention & Health Services Research, American Cancer Society, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Insurance, Health, Insurance Coverage, Lung Neoplasms, Time-to-Treatment. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
The objective of this study was to examine the associations between federal and state short‐term limited‐duration (STLD) insurance plan regulations and timely cancer treatment initiation.
Methods
Adults aged 18–64 years newly diagnosed with female breast, colorectal, or non–small cell lung cancers in 2017–2019 were identified from the National Cancer Database. Patients were categorized into five groups on the basis of their state of residence at diagnosis: (1) the state continuously prohibited STLD plans; (2) the state stopped offering STLD plans after the 2018 federal rule; (3) the state kept the same 3‐month limit on STLD plans before and after the 2018 federal rule; (4) the state expanded the sale of STLD plans but imposed more stringent regulation of STLD plans; and (5) the state expanded the sale of STLD plans and did not impose additional regulation. A difference‐in‐differences (DID) approach examined the changes in the percentages of patients initiating treatment within 30 days of their cancer diagnosis before and after the 2018 federal rule.
Results
For all cancers combined, compared to patients living in states continuously prohibiting STLD plans, a net decrease was observed in the percentages receiving timely treatment among patients living in states continuously limiting STLD plans to 3 months (DID, −1.61 percentage points [ppts]; 95% confidence interval [CI], −2.86 to −0.37 ppts), in states with less stringent regulations (DID, −2.09 ppts; 95% CI, −3.33 to −0.84 ppts), and in states with the least stringent regulations (DID, −2.48 ppts; 95% CI, −3.52 to −1.44 ppts).
Conclusions
Limited or no state regulation of STLD plans after the 2018 federal expansion of plan coverage duration was associated with decreases in timely cancer treatment initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surveillance, Prevention & Health Services Research, American Cancer Society, Atlanta, Georgia, USA.
- Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Jingxuan Zhao, Ilana Graetz, David Howard, K Robin Yabroff, Joseph Lipscomb
Zitieren
APA
Zhao, J., Graetz, I., Howard, D., Yabroff, K. R., & Lipscomb, J. (2026). Federal and state policies regulating short‐term limited‐duration insurance plans and timely cancer treatment initiation. Cancer. https://doi.org/10.1002/cncr.70190
Vancouver
Zhao J, Graetz I, Howard D, Yabroff KR, Lipscomb J. Federal and state policies regulating short‐term limited‐duration insurance plans and timely cancer treatment initiation. Cancer. 2026. doi:10.1002/cncr.70190
BibTeX
@article{Zhao2026,
author = {Zhao, Jingxuan and Graetz, Ilana and Howard, David and Yabroff, K Robin and Lipscomb, Joseph},
title = {Federal and state policies regulating short‐term limited‐duration insurance plans and timely cancer treatment initiation},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70190}
}
EUVIMED